- Home
- APVO vs ORIS Comparison
APVO vs ORIS Comparison
Compare APVO & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- ORIS
- Stock Information
- Founded
- APVO 2016
- ORIS 2014
- Country
- APVO United States
- ORIS China
- Employees
- APVO N/A
- ORIS N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- ORIS Farming/Seeds/Milling
- Sector
- APVO Health Care
- ORIS Consumer Staples
- Exchange
- APVO Nasdaq
- ORIS Nasdaq
- Market Cap
- APVO 4.9M
- ORIS 5.3M
- IPO Year
- APVO N/A
- ORIS 2024
- Fundamental
- Price
- APVO $1.78
- ORIS $0.15
- Analyst Decision
- APVO
- ORIS
- Analyst Count
- APVO 0
- ORIS 0
- Target Price
- APVO N/A
- ORIS N/A
- AVG Volume (30 Days)
- APVO 16.3M
- ORIS 45.4M
- Earning Date
- APVO 11-06-2025
- ORIS 01-01-0001
- Dividend Yield
- APVO N/A
- ORIS N/A
- EPS Growth
- APVO N/A
- ORIS N/A
- EPS
- APVO N/A
- ORIS 0.17
- Revenue
- APVO N/A
- ORIS $15,014,000.00
- Revenue This Year
- APVO N/A
- ORIS N/A
- Revenue Next Year
- APVO N/A
- ORIS N/A
- P/E Ratio
- APVO N/A
- ORIS $1.00
- Revenue Growth
- APVO N/A
- ORIS N/A
- 52 Week Low
- APVO $1.32
- ORIS $0.08
- 52 Week High
- APVO $381.10
- ORIS $56.01
- Technical
- Relative Strength Index (RSI)
- APVO 53.33
- ORIS 45.57
- Support Level
- APVO $1.41
- ORIS $0.15
- Resistance Level
- APVO $1.49
- ORIS $0.19
- Average True Range (ATR)
- APVO 0.18
- ORIS 0.05
- MACD
- APVO 0.04
- ORIS -0.01
- Stochastic Oscillator
- APVO 35.04
- ORIS 5.47
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).